Skip to main content
Premium Trial:

Request an Annual Quote

OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel

NEW YORK (GenomeWeb) — OpGen said today that it has signed an agreement to offer Qiagen nucleic acid purification technology with its Acuitas antimicrobial resistance detection panel.

Under the terms of the deal, Gaithersburg, Maryland-based OpGen will purchase Qiagen's EZ1 Advanced XL automated nucleic acid purification instruments and reagent kits, which enable automated sample preparation throughput of up to 14 samples per one-hour run. OpGen will offer the EZ1 products to its US customers for use with its research-use-only Acuitas AMR Gene Panel u5.47 for the detection of multidrug-resistant bacterial pathogens in urine or bacterial isolates.

Additional terms were not disclosed.

"The EZ1 provides best in class nucleic acid purification technology, and Qiagen's extensive global commercial capabilities and diagnostic expertise should provide multiple opportunities for collaboration in the future," OpGen CEO Evan Jones said in a statement.

This week, Hilden, Germany-based Qiagen reported third quarter revenue growth of 4 percent amid growth in sales of both consumables and instrumentation. OpGen, meanwhile, recently priced a $3.2 million stock offering in order to raise funds to continue developing the Acuitas panel and companion Lighthouse software.